Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:

• Introduction (0:00)
• Overview of Antibody-Drug Conjugates (ADCs) (2:07)
• Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)
• Currently Available ADCs for Gynecologic Cancer Management (26:37)
• Currently Available ADCs for Lung Cancer Management (44:07)
• Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)
• Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)
• Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)

NCPD information and select publications

Featuring an interview with Dr Rana R McKay, including the following topics:

• Prostate Cancer Working Group (PCWG4) revised terminology (0:00)
• Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)
• Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06)
• Takeaways from the Phase III EMBARK study (19:36)
• Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20)
• Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24)

CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics:

• Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00)
• Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35)
• Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13)
• Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (58:55)
• Novel Intravesical Therapies for Nonmetastatic UBC (1:10:20)

NCPD information and select publications

Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics:

• Introduction (0:00)
• Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09)
• Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56)

CME information and select publications

Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O’Shaughnessy and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40)
• Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57)
• Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18)
• Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00)

CME information and select publications

Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics:

• Introduction (0:00)
• Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44)
• Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07)

CME information and select publications

Featuring perspectives from Dr Mrinal Gounder and Dr Richard F Riedel, including the following topics:

• Introduction (0:00)
• Desmoid Tumors — Dr Gounder (2:58)
• Soft Tissue Sarcoma — Dr Riedel (28:29)

CME information and select publications

Featuring perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics:

• Introduction (0:00)
• Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (0:38)
• Nonmetastatic EGFR-Mutated NSCLC, Exon 20 Insertion Mutations and Novel Agents — Dr Piotrowska (33:20)

CME information and select publications

Featuring perspectives from Dr Kevin Punie and Dr Tiffany A Traina, including the following topics:

• Introduction: Where We Are; Where We’re Heading (0:00)
• First-Line Treatment of BRCA Wild-Type Disease (9:14)
• First-Line Treatment of BRCA-Mutant Disease (38:48)
• Novel Approaches (47:49)

CME information and select publications

Featuring perspectives from Dr Ashish M Kamat and Prof Thomas Powles, including the following topics:

• Introduction: Life After Radical Cystectomy (0:00)
• Muscle-Invasive Bladder Cancer — Prof Powles (9:15)
• Non-Muscle-Invasive Bladder Cancer — Dr Kamat (37:49)

CME information and select publications